Investors
and Media
News Releases
-
Apr 4, 2018
SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on March 29, 2018, the Compensation Committee of the Board of...
-
Mar 23, 2018
SOUTH SAN FRANCISCO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
-
Mar 12, 2018
SOUTH SAN FRANCISCO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of John B. Moriarty, J.D., as executive vice president...
-
Mar 12, 2018– Excellent or Good Hemostasis Achieved in 83 Percent of Patients; Thrombotic Events Consistent with High Background Thrombotic Risk –
SOUTH SAN FRANCISCO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced new interim results from ANNEXA-4, the Company’s ongoing Phase 3b/4...
-
Mar 6, 2018
SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Bill Lis, chief executive officer, will present at the following...